SLC5A2 and hydrops fetalis: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) have emerged as a promising first-line treatment option for HF, as it can effectively lower the risk of hospitalization and cardiovascular mortality in patients with HF.